Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation and expansion study of SCTB14 injection in advanced malignant solid tumors
CTR20241479Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB14 in Non-hematologic malignancy, sponsored by Sinocelltech Group Limited. Started Jun 2024; status: active.
02
Drugs
SCTB14
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20241479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241479.